These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18564621)

  • 61. Randomized trial of ondansetron, granisetron, and tropisetron in the prevention of acute nausea and vomiting.
    Lacerda JF; Martins C; Carmo JA; Lourenço MF; Araújo Pereira ME; Rodrigues A; Juncal C; Lacerda JM
    Transplant Proc; 2000 Dec; 32(8):2680-1. PubMed ID: 11134761
    [No Abstract]   [Full Text] [Related]  

  • 62. Always more "setrons": how many do we need?
    Aapro MS
    Support Care Cancer; 1997 Jan; 5(1):1-2. PubMed ID: 9010981
    [No Abstract]   [Full Text] [Related]  

  • 63. Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?
    Blower P; Aapro M
    Br J Cancer; 2002 May; 86(10):1662-3; author reply 1664. PubMed ID: 12085221
    [No Abstract]   [Full Text] [Related]  

  • 64. Palonosetron: more than just another option?
    Di Maio M; Perrone F
    Lancet Oncol; 2009 Feb; 10(2):100-1. PubMed ID: 19185827
    [No Abstract]   [Full Text] [Related]  

  • 65. Is palonosetron also effective for opioid-induced and post-discharge nausea and vomiting?
    Apfel CC; Jukar-Rao S
    Br J Anaesth; 2012 Mar; 108(3):371-3. PubMed ID: 22337957
    [No Abstract]   [Full Text] [Related]  

  • 66. '... setron': are 5-HT3 receptor antagonists different?
    Aapro MS
    Eur J Cancer; 1993; 29A(12):1655. PubMed ID: 8398287
    [No Abstract]   [Full Text] [Related]  

  • 67. Comparison of efficacies of ondansetron and dixyrazine for prophylaxis of emesis during induction treatment in acute myelogenous leukemia. A pilot study.
    Sundström GM; Wahlin A
    Acta Oncol; 1997; 36(2):229-30. PubMed ID: 9140445
    [No Abstract]   [Full Text] [Related]  

  • 68. We're tired of waiting.
    Lichtor JL; Glass PS
    Anesth Analg; 2008 Aug; 107(2):353-5. PubMed ID: 18633005
    [No Abstract]   [Full Text] [Related]  

  • 69. Palonosetron-induced migraine-type headache.
    Jain A
    Can J Anaesth; 2011 Feb; 58(2):230-1. PubMed ID: 21132477
    [No Abstract]   [Full Text] [Related]  

  • 70. Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients.
    Avritscher EB; Shih YC; Sun CC; Gralla RJ; Grunberg SM; Xu Y; Elting LS
    J Support Oncol; 2010; 8(6):242-51. PubMed ID: 21265391
    [TBL] [Abstract][Full Text] [Related]  

  • 71. NCCN Guidelines Insights: Antiemesis, Version 2.2017.
    Berger MJ; Ettinger DS; Aston J; Barbour S; Bergsbaken J; Bierman PJ; Brandt D; Dolan DE; Ellis G; Kim EJ; Kirkegaard S; Kloth DD; Lagman R; Lim D; Loprinzi C; Ma CX; Maurer V; Michaud LB; Nabell LM; Noonan K; Roeland E; Rugo HS; Schwartzberg LS; Scullion B; Timoney J; Todaro B; Urba SG; Shead DA; Hughes M
    J Natl Compr Canc Netw; 2017 Jul; 15(7):883-893. PubMed ID: 28687576
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Pharmacokinetic and pharmacodynamic features of palonosetron].
    Genazzani AA; Billington RA
    Tumori; 2008; 94(2):suppl 6-13. PubMed ID: 18564620
    [No Abstract]   [Full Text] [Related]  

  • 73. Palonosetron induced anaphylaxis in an adult female.
    Gupta YK; Shanmugam SP; Padhy BM; Goyal A
    Br J Clin Pharmacol; 2010 Jul; 70(1):149-50. PubMed ID: 20642559
    [No Abstract]   [Full Text] [Related]  

  • 74. Surrogate outcomes: meaningful not!
    Fisher DM
    Anesthesiology; 1999 Feb; 90(2):355-6. PubMed ID: 9952135
    [No Abstract]   [Full Text] [Related]  

  • 75. Treatment of postoperative nausea and vomiting with dolasetron versus ondansetron: is there a conflict of interest?
    White PF
    Anesth Analg; 2005 Dec; 101(6):1887. PubMed ID: 16301287
    [No Abstract]   [Full Text] [Related]  

  • 76. Approval of dolasetron expands antiemetic choices.
    Am J Health Syst Pharm; 1998 Jan; 55(1):18, 20. PubMed ID: 9437470
    [No Abstract]   [Full Text] [Related]  

  • 77. Seizure associated with palonosetron.
    Zambelli A; Sagrada P; Pavesi L
    Support Care Cancer; 2009 Mar; 17(3):217. PubMed ID: 19139929
    [No Abstract]   [Full Text] [Related]  

  • 78. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis.
    Leibundgut U; Lancranjan I
    Lancet; 1987 May; 1(8543):1198. PubMed ID: 2883502
    [No Abstract]   [Full Text] [Related]  

  • 79. LAS 30451: a novel 5-HT3 antagonist.
    Martin M; Rosell R; Guillem V; Díaz-Rubio E; Moreno I; Soriano V; Fernández A; Pérez A
    Eur J Cancer; 1993; 29A Suppl 1():S33-4. PubMed ID: 8427723
    [No Abstract]   [Full Text] [Related]  

  • 80. New drugs 04. Part III.
    Hussar DA
    Nursing; 2004 Sep; 34(9):56-62; quiz 63-4. PubMed ID: 15382384
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.